Share Price and Basic Stock Data
Last Updated: January 2, 2026, 10:01 pm
| PEG Ratio | 24.50 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Inject (Kerala) Ltd, operating in the pharmaceuticals sector, has shown a notable evolution in its revenue streams, reflecting a significant recovery from previous years. The company’s sales stood at ₹0.17 Cr for FY 2023, a substantial increase from ₹0.02 Cr in FY 2022. This upward trajectory continued with projected revenues of ₹5.79 Cr for FY 2024 and further escalated to ₹19.05 Cr for FY 2025. The quarterly sales figures corroborate this growth, with the latest recorded sales of ₹0.22 Cr in Dec 2023, indicating a positive trend as the company ramps up its operations. However, the sales figures have been sporadic, with periods of zero revenue, notably in Mar 2023 and Sep 2023. This inconsistency highlights the need for sustained operational efficiency and market penetration strategies to stabilize income streams. Overall, the company’s sales growth signals a potential turnaround, but the historical volatility necessitates cautious optimism.
Profitability and Efficiency Metrics
Gujarat Inject (Kerala) Ltd’s profitability metrics indicate a gradual improvement, although the figures remain below industry norms. The operating profit margin (OPM) recorded a significant recovery, reaching 5.62% for FY 2025, compared to a negative OPM of -217.65% in FY 2023. This turnaround reflects improved cost management and operational efficiencies. Net profit for FY 2025 is reported at ₹1.02 Cr, translating to a net profit margin of 5.34%. Despite these improvements, the company’s P/E ratio stands at 125, suggesting that the stock might be valued at a premium relative to its earnings, which could deter some investors. The interest coverage ratio (ICR) is exceptionally high at 861.55, indicating robust earnings relative to interest payments, but the absence of debt (borrowings stand at ₹0.00 Cr) raises questions about growth funding strategies. The company must focus on enhancing profitability further to align with sector averages, which typically hover around 15-20% for OPM.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gujarat Inject (Kerala) Ltd reveals a mixed picture of financial health. The total assets reported for FY 2025 are ₹11.95 Cr, with total liabilities also increasing to ₹11.95 Cr, resulting in a precarious equity situation. Reserves remain negative at ₹-4.62 Cr, reflecting accumulated losses, which could hinder future growth and investment capabilities. The company maintains a current ratio of 5.15, significantly above the typical threshold of 1, indicating strong liquidity and the ability to cover short-term obligations. However, the book value per share is reported at ₹6.84, suggesting limited shareholder equity. The company’s return on equity (ROE) is at 10.15%, which, while positive, is lower than many competitors in the pharmaceuticals sector. The absence of borrowings indicates a conservative financial approach, but it may also suggest under-leveraging in capital structure that could limit growth opportunities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gujarat Inject (Kerala) Ltd is predominantly public, with 100% public ownership recorded in most recent quarters. The number of shareholders has increased from 6,341 in Dec 2022 to 8,151 in Sep 2025, indicating growing investor interest and confidence in the company’s recovery trajectory. The absence of institutional investors, both foreign and domestic, could reflect a cautious approach from larger entities, potentially due to the company’s historical volatility in sales and profitability. This high public ownership, while indicative of grassroots support, also raises concerns about the lack of institutional backing, which is often seen as a stabilizing force in equity markets. The company must work on enhancing visibility and credibility among institutional investors to attract larger capital inflows, which could provide necessary funds for expansion and operational improvements.
Outlook, Risks, and Final Insight
Looking ahead, Gujarat Inject (Kerala) Ltd faces a pivotal moment as it seeks to capitalize on its recent growth trends while addressing inherent risks. Strengths include a robust liquidity position, as indicated by a high current ratio, and a remarkable interest coverage ratio, suggesting financial stability. However, risks loom from a high P/E ratio, indicating potential overvaluation, and negative reserves, which could impact long-term sustainability. The company’s ability to maintain consistent revenue growth and profitability will be critical in attracting institutional investors and enhancing shareholder value. Future scenarios could see the company either solidifying its market position through effective operational strategies or facing challenges if it fails to sustain its revenue growth amidst competitive pressures. In conclusion, while Gujarat Inject (Kerala) Ltd has made strides in recovery, continued focus on profitability and strategic investor engagement will be crucial for future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 217/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,749 Cr. | 435 | 479/192 | 98.3 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,252.27 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.03 | 0.10 | 0.00 | 0.15 | 0.00 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 | 1.58 |
| Expenses | 0.39 | 0.10 | 0.02 | 0.11 | 0.00 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 | 1.55 |
| Operating Profit | -0.36 | 0.00 | -0.02 | 0.04 | 0.00 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.10 | 0.03 |
| OPM % | -1,200.00% | 0.00% | 26.67% | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | 1.90% | ||
| Other Income | 0.40 | 0.00 | 0.03 | 0.00 | 0.02 | 0.04 | 0.00 | 0.00 | 0.17 | 0.00 | 0.01 | 0.00 | 0.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.04 | 0.00 | 0.01 | 0.04 | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.10 | 0.10 | 0.09 |
| Tax % | 25.00% | 0.00% | 25.00% | 0.00% | 0.00% | 20.00% | 23.53% | 14.08% | 25.00% | 30.00% | 20.00% | 22.22% | |
| Net Profit | 0.03 | 0.00 | 0.01 | 0.03 | 0.01 | 0.00 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 | 0.07 |
| EPS in Rs | 0.06 | 0.00 | 0.02 | 0.06 | 0.02 | 0.00 | 0.04 | 0.08 | 0.42 | 0.14 | 0.05 | 0.05 | 0.05 |
Last Updated: December 26, 2025, 4:50 pm
Below is a detailed analysis of the quarterly data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.58 Cr.. The value appears to be declining and may need further review. It has decreased from 2.42 Cr. (Jun 2025) to 1.58 Cr., marking a decrease of 0.84 Cr..
- For Expenses, as of Sep 2025, the value is 1.55 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.32 Cr. (Jun 2025) to 1.55 Cr., marking a decrease of 0.77 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.03 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Jun 2025) to 0.03 Cr., marking a decrease of 0.07 Cr..
- For OPM %, as of Sep 2025, the value is 1.90%. The value appears to be declining and may need further review. It has decreased from 4.13% (Jun 2025) to 1.90%, marking a decrease of 2.23%.
- For Other Income, as of Sep 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.06 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Jun 2025) to 0.09 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Sep 2025, the value is 22.22%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Jun 2025) to 22.22%, marking an increase of 2.22%.
- For Net Profit, as of Sep 2025, the value is 0.07 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.07 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.05. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 11.39 |
| Expenses | 0.00 | 0.00 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 10.89 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 0.50 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 4.39% | |||||
| Other Income | 0.00 | 0.00 | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.07 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 0.57 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | |||||
| Net Profit | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 0.42 |
| EPS in Rs | 0.00 | 0.00 | 4.69 | 0.02 | -0.04 | -0.02 | 0.00 | -0.22 | 0.00 | 0.08 | 0.07 | 0.70 | 0.29 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -99.57% | -300.00% | 50.00% | 100.00% | 100.00% | 100.00% | 1175.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.43% | 350.00% | 50.00% | 0.00% | 0.00% | 1075.00% |
Gujarat Inject (Kerala) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 884% |
| TTM: | 112% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 465% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 47% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 11% |
Last Updated: September 5, 2025, 3:40 pm
Balance Sheet
Last Updated: December 10, 2025, 4:26 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.64 | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -4.48 |
| Borrowings | 2.55 | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.38 | 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 1.55 |
| Total Liabilities | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Total Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
Below is a detailed analysis of the balance sheet data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.63 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.63 Cr..
- For Reserves, as of Sep 2025, the value is -4.48 Cr.. The value appears to be improving (becoming less negative). It has improved from -4.62 Cr. (Mar 2025) to -4.48 Cr., marking an improvement of 0.14 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.55 Cr.. The value appears to be improving (decreasing). It has decreased from 1.94 Cr. (Mar 2025) to 1.55 Cr., marking a decrease of 0.39 Cr..
- For Total Liabilities, as of Sep 2025, the value is 11.70 Cr.. The value appears to be improving (decreasing). It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 11.70 Cr.. The value appears to be declining and may need further review. It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
- For Total Assets, as of Sep 2025, the value is 11.70 Cr.. The value appears to be declining and may need further review. It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.48 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.55 | -2.86 | -0.56 | -0.56 | -0.66 | -0.62 | -0.60 | -0.81 | -0.78 | -0.98 | 0.05 | 1.07 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 167.06 | 137.76 | |||||
| ROCE % | 2.65% | 13.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.13 | 0.09 | 0.05 | 0.00 | -0.12 |
| Diluted EPS (Rs.) | 1.13 | 0.09 | 0.05 | 0.00 | -0.12 |
| Cash EPS (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Revenue From Operations / Share (Rs.) | 13.01 | 5.13 | 0.35 | 0.04 | 0.02 |
| PBDIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| Net Profit / Share (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| PBDIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBT Margin (%) | 6.58 | 1.81 | 31.93 | 13.05 | -911.24 |
| Net Profit Margin (%) | 5.34 | 1.42 | 23.62 | 9.77 | -911.24 |
| Return on Networth / Equity (%) | 10.15 | 0.96 | -4.90 | -0.25 | 0.00 |
| Return on Capital Employeed (%) | 12.53 | 1.23 | -14.62 | -0.64 | 22.60 |
| Return On Assets (%) | 8.51 | 0.95 | 13.53 | 3.41 | -599.51 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -0.54 | -0.47 | -0.47 |
| Total Debt / Equity (X) | 0.00 | 0.00 | -0.72 | -0.83 | -0.78 |
| Asset Turnover Ratio (%) | 1.85 | 1.29 | 0.94 | 0.54 | 0.72 |
| Current Ratio (X) | 5.15 | 40.77 | 0.10 | 0.04 | 0.02 |
| Quick Ratio (X) | 5.15 | 40.77 | 0.10 | 0.04 | 0.02 |
| Interest Coverage Ratio (X) | 861.55 | 237.71 | 1108.59 | 144.19 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 698.99 | 187.11 | 820.29 | 108.27 | 0.00 |
| Enterprise Value (Cr.) | 38.02 | 8.32 | 4.38 | 1.48 | 0.00 |
| EV / Net Operating Revenue (X) | 2.00 | 1.44 | 25.18 | 65.66 | 0.00 |
| EV / EBITDA (X) | 30.29 | 78.68 | 78.78 | 499.58 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 1.94 | 22.04 | 33.50 | 0.00 |
| Price / BV (X) | 3.80 | 1.31 | -4.57 | -0.86 | 0.00 |
| Price / Net Operating Revenue (X) | 2.00 | 1.94 | 22.08 | 33.70 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Gujarat Inject (Kerala) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 1.13, marking an increase of 1.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 1.13, marking an increase of 1.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 3. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.01. It has increased from 5.13 (Mar 24) to 13.01, marking an increase of 7.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 2. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For PBDIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBT Margin (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 10. It has increased from 1.81 (Mar 24) to 6.58, marking an increase of 4.77.
- For Net Profit Margin (%), as of Mar 25, the value is 5.34. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 5.34, marking an increase of 3.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 15. It has increased from 0.96 (Mar 24) to 10.15, marking an increase of 9.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.53. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 12.53, marking an increase of 11.30.
- For Return On Assets (%), as of Mar 25, the value is 8.51. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 8.51, marking an increase of 7.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.85. It has increased from 1.29 (Mar 24) to 1.85, marking an increase of 0.56.
- For Current Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has decreased from 40.77 (Mar 24) to 5.15, marking a decrease of 35.62.
- For Quick Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 2. It has decreased from 40.77 (Mar 24) to 5.15, marking a decrease of 35.62.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 861.55. This value is within the healthy range. It has increased from 237.71 (Mar 24) to 861.55, marking an increase of 623.84.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 698.99. This value is within the healthy range. It has increased from 187.11 (Mar 24) to 698.99, marking an increase of 511.88.
- For Enterprise Value (Cr.), as of Mar 25, the value is 38.02. It has increased from 8.32 (Mar 24) to 38.02, marking an increase of 29.70.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 2.00, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 30.29. This value exceeds the healthy maximum of 15. It has decreased from 78.68 (Mar 24) to 30.29, marking a decrease of 48.39.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For Price / BV (X), as of Mar 25, the value is 3.80. This value exceeds the healthy maximum of 3. It has increased from 1.31 (Mar 24) to 3.80, marking an increase of 2.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Inject (Kerala) Ltd:
- Net Profit Margin: 5.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.53% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.15% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 698.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 128 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shop No. 15, K-Tower, Haveli Resi-Cum Plaza, Vadodra Gujarat 390014 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murli Nair | Chairman & Wholetime Director |
| Ms. Reena Mahatma | Non Executive Director |
| Mr. Rushiraj Zaverbhai Patel | Non Exe. & Ind. Director |
| Mr. Nileshbhai Vinubhai Rangholiya | Non Exe. & Ind. Director |
FAQ
What is the intrinsic value of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd's intrinsic value (as of 02 January 2026) is ₹79.62 which is 117.54% higher the current market price of ₹36.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹53.6 Cr. market cap, FY2025-2026 high/low of ₹37.0/17.0, reserves of ₹-4.48 Cr, and liabilities of ₹11.70 Cr.
What is the Market Cap of Gujarat Inject (Kerala) Ltd?
The Market Cap of Gujarat Inject (Kerala) Ltd is 53.6 Cr..
What is the current Stock Price of Gujarat Inject (Kerala) Ltd as on 02 January 2026?
The current stock price of Gujarat Inject (Kerala) Ltd as on 02 January 2026 is ₹36.6.
What is the High / Low of Gujarat Inject (Kerala) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Inject (Kerala) Ltd stocks is ₹37.0/17.0.
What is the Stock P/E of Gujarat Inject (Kerala) Ltd?
The Stock P/E of Gujarat Inject (Kerala) Ltd is 128.
What is the Book Value of Gujarat Inject (Kerala) Ltd?
The Book Value of Gujarat Inject (Kerala) Ltd is 6.93.
What is the Dividend Yield of Gujarat Inject (Kerala) Ltd?
The Dividend Yield of Gujarat Inject (Kerala) Ltd is 0.00 %.
What is the ROCE of Gujarat Inject (Kerala) Ltd?
The ROCE of Gujarat Inject (Kerala) Ltd is 13.5 %.
What is the ROE of Gujarat Inject (Kerala) Ltd?
The ROE of Gujarat Inject (Kerala) Ltd is 11.0 %.
What is the Face Value of Gujarat Inject (Kerala) Ltd?
The Face Value of Gujarat Inject (Kerala) Ltd is 10.0.